With Clue and Lovehoney as partners, Evaro secures €21 million to expand NHS-licensed embedded health services

Norwich-based Evaro, an NHS-licensed digital healthcare platform serving over 2 million patients, today announced it has closed a €21 million ($25 million) Series A funding round to expand across treatment areas (women’s health, men’s health, and longevity medicine), clinical capabilities such as cutting edge diagnostics and aftercare, and platform development (API-first infrastructure for seamless brand integration).

The round was led by AlbionVC, with participation from Simplyhealth Ventures, Exceptional Ventures, Cornerstone VC, and BBI. The platform already partners with period-tracking app Clue and sexual wellness retailer Lovehoney, embedding prescription services directly into their customer experiences.

This comes two years after their 2024 €1.4 million Seed round, as reported by EU-Startups.

Dr Thuria Wenbar, CEO and co-founder of Evaro, said: “When a third of people are waiting over a week just to see their GP, it’s time to think through alternative solutions that help people get the care they need while supporting NHS capacity. What we’ve built is infrastructure that allows our partners – brands people already trust – to deliver safe and regulated healthcare for common conditions without having to build a thing.

“We’re making healthcare as accessible as online banking, and this funding lets us prove that model works at scale.”

In the 2025–2026 European HealthTech funding landscape, Evaro’s Series A aligns with a steady flow of capital into regulated, platform-driven and clinically focused digital healthcare models.

In Spain, Tucuvi raised €17 million to scale its voice-AI platform for automated patient follow-up within healthcare systems. In the UK, GlycanAge secured €7.4 million to advance glycan-based ageing diagnostics, reflecting adjacent investment into validated diagnostics and longevity medicine — one of Evaro’s stated expansion areas.

Earlier-stage rounds also point to the same structural themes: Norway-based Noteless raised €3.5 million to reduce clinician workload through AI documentation, while Copenhagen’s Teton.ai closed a €17 million Series A to develop predictive intelligence for hospital care. Poland’s Holi added a further €3 million to expand its digital obesity treatment platform.

Taken together, these rounds amount to approximately €48.9 million in disclosed funding and underline a broader trend towards scalable, regulated healthcare infrastructure and digital platforms – providing context for Evaro’s raise as part of a wider European push to relieve pressure on health systems through embedded, technology-enabled care.

“We’ve seen embedded finance transform banking, Evaro is now driving the embedded health revolution,” said Christoph Ruedig, Partner at AlbionVC, who joins Evaro’s board. “Evaro has spent seven years building its infrastructure properly, with deep regulatory credentials. This now allows consumer brands to enter the healthcare space safely, unlocking massive latent demand while relieving pressure on the NHS. We are thrilled to back the team as they define this new category.”

Founded in 2018 by emergency physician Dr Thuria Wenbar and pharmacist researcher Dr Oskar Wenbar, Evaro serves three distinct markets: consumer brands wanting to generate new revenue; healthcare providers expanding digital capacity for common conditions; and employers deploying health benefits.

Evaro enables any brand to offer prescription medication directly to their customers. The company has served over 2 million patients and is one of the few online pharmacy providers to hold Care Quality Commission, General Pharmaceutical Council, and NHS licenses simultaneously.

The funding comes as 20.5 million people experienced month-long waits for a GP appointment in 2024, up 60% in seven years.

Evaro looks to help alleviate the burden on the NHS by providing complete regulated healthcare infrastructure – asynchronous consultations allowing speed and discretion of care, remote diagnostics, prescribing, dispensing, and aftercare – that can be embedded into any platform people spend time on within days.

For partners, can potentially offer a new revenue stream with minimal implementation burden – integrations can reportedly be completed in as little as 2 weeks – while deepening customer relationships through an expanded health offering.

A 2023 BJGP Open study found well-designed asynchronous consultations can resolve up to 66% of primary care cases without live appointments.

Dr Oskar Wenbar, Chief Medical Officer and co-founder, adds: “Patients now expect the same convenience from healthcare that they get from banking or shopping – instant, mobile, on their terms. The technology exists to deliver this for minor conditions, but our system is still stuck requiring appointments, phone calls, physical visits – with no capacity for smart aftercare. We want to solve this, and scale the infrastructure that matches how people actually want to access care in 2026.”

The company aims to serve 10 million patients over the next three years while establishing healthcare-as-a-service as a new category in the UK market.

The post With Clue and Lovehoney as partners, Evaro secures €21 million to expand NHS-licensed embedded health services appeared first on EU-Startups.